Please assess the completion status of the following clinical trial:

Trial Title: Paclitaxel, Cisplatin, and Filgrastim Combined With Radiation Therapy in Treating Patients With Locally Recurrent Head and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven locally recurrent primary squamous cell cancer (SCC) of the head and neck or second primary SCC of the head and neck~  * More than 1 prior recurrence allowed if the first recurrence occurred at least 6 months after completion of prior radiotherapy~* Disease must be confined to the head and neck (above the clavicles)~* No primary SCC of the nasopharynx or salivary gland~* Prior irradiation of 45-75 Gy to the majority (75% or greater) of tumor volume~* Entire tumor volume must be included in a treatment field that limits the total spinal cord dose (prior and anticipated) to 50 Gy~  * Prior radiotherapy records, including simulation and portal films, available in order to assure that cord tolerance is not exceeded~* Measurable disease~* Ineligible for complete surgical resection~* No distant metastases~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Zubrod 0 or 1~Life expectancy:~* No other concurrent illness that would limit survival~Hematopoietic:~* Granulocyte count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than 1.5 mg/dL~* Serum glutamate oxaloacetate transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) no greater than 2 times normal\*~* Alkaline phosphatase no greater than 2 times normal\*~* \* Greater than 2 times normal allowed if no metastases by liver ultrasound or CT scan~Renal:~* Creatinine no greater than 1.5 mg/dL~Other:~* No other invasive malignancy within the past 2 years except in situ malignancies (e.g., carcinoma in situ of the cervix, carcinoma in situ of the breast, or nonmelanoma skin cancer)~* No other concurrent illness that would impair tolerance to therapy~* No grade 2 or worse pre-existing peripheral sensory neuropathy~* No hypersensitivity to E. coli derived products~* Not pregnant or nursing~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* Prior chemotherapy allowed as a component of the primary treatment~* No prior chemotherapy for recurrent disease~* At least 6 months since prior chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* See Disease Characteristics~* At least 6 months since prior radiotherapy~Surgery:~* See Disease Characteristics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radiation (BID) and chemotherapy (Type: EXPERIMENTAL): Radiation (BID), cisplatin and paclitaxel given on days 1-5 (Monday-Friday) in weeks 1, 3, 5 and 7. G-CSF given on days 6-13.

Based on this trial design, predict the completion outcome and termination type (if applicable).